CSL Behring Plans $240 Million Expansion At Its Kankakee, Illinois, Operations Center
According to the firm, its production expansion is designed to meet a growing need for its lifesaving and life-improving therapies, used to treat patients with rare and serious medical disorders around the world.
CSL Behring plans production capacity increases of plasma intermediates at its Kankakee site and albumin at its Broadmeadows facility in Australia. At Kankakee, the expansion will substantially increase the production of plasma intermediates. CSL Behring uses plasma intermediates to make albumin and immunoglobulins. The expansion is expected to be completed in 2017, at which time 300,000 square feet will have been added to the site. Of the $450 million investment, $240 million will be for Kankakee and $210 million for Broadmeadows.
The announcement follows the U.S. Food and Drug Administration's recent regulatory approval to commence operations from a previous expansion of Kankakee's manufacturing operation, which added 140,000 square feet.
The cross-functionality that is enabled by the capacity expansions will allow CSL Behring to leverage its global manufacturing network, helping to optimize the manufacturing efficiencies of immunoglobulin and albumin. “Our latest production expansion means the critical base material for our leading therapies will continue to be available -- enabling us to deliver on our promise to patients around the world," said CEO Paul Perreault.
Georgia-Pacific Consumer Products Group Plans $100 Million Expansion at Bowling Green, Kentucky Plant
2018 Leading Metro Locations: Pacific and Mountain Metros Dominate the List
33rd Annual Corporate Survey & the 15th Annual Consultants Survey
2018 Top States for Doing Business: Georgia Ranks #1 Fifth Year in a Row
Made in America: An Outlook for Manufacturing in the U.S.
Location USA 2018
A Changing Food Manufacturing Industry
2017 Food Processing
Opportunity Zones Can Uplift Communities and Investors Alike